Herikstad H, Hayes P, Mokhtar M, Fracaro M L, Threlfall E J, Angulo F J
Centers for Disease Control and Prevention, Atlanta, Gerogia, USA.
Emerg Infect Dis. 1997 Jul-Sep;3(3):371-2. doi: 10.3201/eid0303.970316.
We conducted a national survey of antimicrobial resistance in human clinical isolates of Salmonella between July 1, 1994, and June 30, 1995. Every tenth nontyphoidal Salmonella isolate received at state public health laboratories in the United States during this period was tested for resistance to 12 antimicrobial agents, including two quinolones, nalidixic acid, and ciprofloxacin. Emerging quinolone resistance was detected; of 4,008 isolates tested, 21 (0.5%) were resistant to nalidixic acid, and one (0.02%) was resistant to ciprofloxacin. Continued surveillance for quinolone-resistant Salmonella is necessary, particularly after the recent approval of a fluoroquinolone for use in animals intended for food in the United States.
1994年7月1日至1995年6月30日期间,我们对沙门氏菌人类临床分离株的抗菌药物耐药性进行了一项全国性调查。在此期间,美国各州公共卫生实验室收到的每十株非伤寒沙门氏菌分离株都被检测了对12种抗菌药物的耐药性,其中包括两种喹诺酮类药物,即萘啶酸和环丙沙星。检测到了新出现的喹诺酮类耐药性;在4008株受试分离株中,21株(0.5%)对萘啶酸耐药,1株(0.02%)对环丙沙星耐药。有必要持续监测耐喹诺酮类沙门氏菌,特别是在美国最近批准一种氟喹诺酮类药物用于食用动物之后。